Bachem Holding AG

LSE:0QND Stock Report

Market Cap: CHF 4.2b

Bachem Holding Valuation

Is 0QND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 25.92
Fair Value
116.0% overvalued intrinsic discount
7
Number of Analysts

Below Fair Value: 0QND (CHF55.99) is trading above our estimate of fair value (CHF25.92)

Significantly Below Fair Value: 0QND is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QND?

Key metric: As 0QND is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QND. This is calculated by dividing 0QND's market cap by their current earnings.
What is 0QND's PE Ratio?
PE Ratio37x
EarningsCHF 113.57m
Market CapCHF 4.21b

Price to Earnings Ratio vs Peers

How does 0QND's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average52.3x
HVO hVIVO
7.1x-29.6%UK£123.1m
HIK Hikma Pharmaceuticals
19.8x11.0%UK£4.6b
GNS Genus
149.8x36.9%UK£1.2b
SFZN Siegfried Holding
32.7x13.0%CHF 4.2b
0QND Bachem Holding
37x17.8%CHF 4.2b

Price-To-Earnings vs Peers: 0QND is good value based on its Price-To-Earnings Ratio (37x) compared to the peer average (52.3x).

Price to Earnings Ratio vs Industry

How does 0QND's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0QND 37.0xIndustry Avg. 36.3xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QND is expensive based on its Price-To-Earnings Ratio (37x) compared to the European Life Sciences industry average (36.3x).

Price to Earnings Ratio vs Fair Ratio

What is 0QND's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QND PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37x
Fair PE Ratio29.2x

Price-To-Earnings vs Fair Ratio: 0QND is expensive based on its Price-To-Earnings Ratio (37x) compared to the estimated Fair Price-To-Earnings Ratio (29.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 55.99
CHF 76.86
+37.3%
16.3%CHF 100.00CHF 58.00n/a7
Jan ’26CHF 58.00
CHF 83.57
+44.1%
13.8%CHF 100.00CHF 71.00n/a7
Dec ’25CHF 67.70
CHF 84.43
+24.7%
12.7%CHF 100.00CHF 71.00n/a7
Nov ’25CHF 69.89
CHF 84.83
+21.4%
13.2%CHF 100.00CHF 71.00n/a6
Oct ’25CHF 70.25
CHF 82.83
+17.9%
16.0%CHF 100.00CHF 65.00n/a6
Sep ’25CHF 81.33
CHF 82.83
+1.8%
16.0%CHF 100.00CHF 65.00n/a6
Aug ’25CHF 79.05
CHF 77.14
-2.4%
22.9%CHF 100.00CHF 52.00n/a7
Jul ’25CHF 83.65
CHF 75.67
-9.5%
22.1%CHF 100.00CHF 52.00n/a6
Jun ’25CHF 80.85
CHF 70.80
-12.4%
19.6%CHF 85.00CHF 52.00n/a5
May ’25CHF 80.15
CHF 70.80
-11.7%
19.6%CHF 85.00CHF 52.00n/a5
Apr ’25CHF 86.42
CHF 70.80
-18.1%
19.6%CHF 85.00CHF 52.00n/a5
Mar ’25CHF 68.70
CHF 71.17
+3.6%
17.6%CHF 85.00CHF 52.00n/a6
Feb ’25CHF 58.21
CHF 71.17
+22.3%
17.6%CHF 85.00CHF 52.00n/a6
Jan ’25CHF 65.01
CHF 73.17
+12.5%
13.7%CHF 85.00CHF 56.00CHF 58.006
Dec ’24CHF 63.76
CHF 75.33
+18.2%
9.3%CHF 85.00CHF 64.00CHF 67.706
Nov ’24CHF 65.30
CHF 75.33
+15.4%
9.3%CHF 85.00CHF 64.00CHF 69.896
Oct ’24CHF 68.65
CHF 77.00
+12.2%
12.7%CHF 95.00CHF 64.00CHF 70.256
Sep ’24CHF 82.05
CHF 80.00
-2.5%
14.1%CHF 97.00CHF 65.00CHF 81.337
Aug ’24CHF 80.35
CHF 82.83
+3.1%
13.6%CHF 97.00CHF 65.00CHF 79.056
Jul ’24CHF 77.20
CHF 87.60
+13.5%
9.3%CHF 97.00CHF 74.00CHF 83.655
Jun ’24CHF 94.72
CHF 91.75
-3.1%
4.8%CHF 97.00CHF 86.00CHF 80.854
May ’24CHF 97.09
CHF 88.20
-9.2%
11.2%CHF 100.00CHF 71.00CHF 80.155
Apr ’24CHF 91.40
CHF 88.20
-3.5%
11.2%CHF 100.00CHF 71.00CHF 86.425
Mar ’24CHF 93.95
CHF 88.20
-6.1%
11.2%CHF 100.00CHF 71.00CHF 68.705
Feb ’24CHF 80.90
CHF 86.80
+7.3%
11.7%CHF 100.00CHF 71.00CHF 58.215
Jan ’24CHF 79.85
CHF 86.80
+8.7%
11.7%CHF 100.00CHF 71.00CHF 65.015
Analyst Price Target
Consensus Narrative from 7 Analysts
CHF 76.70
Fair Value
27.0% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 13:15
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bachem Holding AG is covered by 23 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Konstantin WiechertBaader Helvea Equity Research